NewAmsterdam Pharma Company NVNASDAQ:NAMS
- LAST PRICE19.6900
- TODAY'S CHANGE (%)-0.3600 (-1.7955%)
- Bid / Lots19.6100/ 7
- Ask / Lots19.7300/ 3
- Open / Previous Close21.1400 / 20.0500
- Day Range
- 52 Week Range
- Volume172,881
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NAMS |
|---|---|---|
| 09:32 ET | 24272 | 21.14 |
| 09:34 ET | 453 | 20.325 |
| 09:38 ET | 200 | 20.31 |
| 09:39 ET | 100 | 20.345 |
| 09:59 ET | 1001 | 20.51 |
| 10:01 ET | 432 | 20.32 |
| 10:03 ET | 200 | 20.35 |
| 10:12 ET | 2700 | 20.47 |
| 10:14 ET | 500 | 20.35 |
| 10:15 ET | 100 | 20.57 |
| 10:17 ET | 100 | 20.47 |
| 10:21 ET | 100 | 20.475 |
| 10:33 ET | 200 | 20.52 |
| 10:37 ET | 700 | 20.445 |
| 10:39 ET | 726 | 20.18 |
| 10:42 ET | 354 | 20.35 |
| 10:51 ET | 1829 | 20.31 |
| 10:53 ET | 100 | 20.31 |
| 10:55 ET | 2993 | 20.11 |
| 11:02 ET | 625 | 20.11 |
| 11:04 ET | 100 | 20.18 |
| 11:15 ET | 9582 | 20.09 |
| 11:18 ET | 10792 | 19.81 |
| 11:20 ET | 600 | 19.89 |
| 11:22 ET | 2271 | 20.14 |
| 11:24 ET | 275 | 20.23 |
| 11:26 ET | 300 | 20.16 |
| 11:27 ET | 400 | 20.285 |
| 11:31 ET | 550 | 20.325 |
| 11:33 ET | 600 | 20.1 |
| 11:36 ET | 200 | 20.09 |
| 11:42 ET | 200 | 20.115 |
| 11:51 ET | 200 | 20.01 |
| 11:54 ET | 200 | 20.01 |
| 11:56 ET | 500 | 20.08 |
| 11:58 ET | 200 | 20.03 |
| 12:03 ET | 1143 | 19.905 |
| 12:05 ET | 311 | 19.8 |
| 12:07 ET | 7828 | 20.07 |
| 12:09 ET | 1948 | 20 |
| 12:12 ET | 798 | 20.055 |
| 12:14 ET | 3770 | 20.11 |
| 12:18 ET | 4690 | 20.09 |
| 12:20 ET | 550 | 20.01 |
| 12:21 ET | 992 | 20.01 |
| 12:25 ET | 300 | 20.01 |
| 12:30 ET | 100 | 20.01 |
| 12:32 ET | 300 | 20.075 |
| 12:36 ET | 300 | 20.075 |
| 12:38 ET | 100 | 20.03 |
| 12:39 ET | 6869 | 20 |
| 12:41 ET | 29958 | 19.87 |
| 12:43 ET | 100 | 19.86 |
| 12:45 ET | 1023 | 19.62 |
| 12:48 ET | 400 | 19.51 |
| 12:50 ET | 2214 | 19.73 |
| 12:52 ET | 767 | 19.9 |
| 12:56 ET | 700 | 19.82 |
| 12:57 ET | 200 | 19.84 |
| 01:03 ET | 100 | 19.81 |
| 01:08 ET | 200 | 19.87 |
| 01:14 ET | 100 | 19.75 |
| 01:15 ET | 100 | 19.55 |
| 01:21 ET | 244 | 19.53 |
| 01:44 ET | 100 | 19.53 |
| 01:48 ET | 200 | 19.53 |
| 01:50 ET | 208 | 19.65 |
| 01:51 ET | 736 | 19.89 |
| 02:00 ET | 200 | 19.88 |
| 02:09 ET | 100 | 19.797 |
| 02:11 ET | 794 | 19.74 |
| 02:13 ET | 200 | 19.66 |
| 02:15 ET | 100 | 19.66 |
| 02:20 ET | 100 | 19.65 |
| 02:22 ET | 300 | 19.64 |
| 02:24 ET | 100 | 19.64 |
| 02:26 ET | 350 | 19.64 |
| 02:27 ET | 859 | 19.72 |
| 02:29 ET | 1396 | 19.62 |
| 02:31 ET | 400 | 19.62 |
| 02:33 ET | 302 | 19.52 |
| 02:36 ET | 100 | 19.51 |
| 02:38 ET | 450 | 19.44 |
| 02:40 ET | 200 | 19.43 |
| 02:42 ET | 292 | 19.47 |
| 02:44 ET | 200 | 19.47 |
| 02:45 ET | 530 | 19.47 |
| 02:47 ET | 209 | 19.55 |
| 02:49 ET | 100 | 19.635 |
| 02:51 ET | 200 | 19.54 |
| 02:54 ET | 600 | 19.6 |
| 02:56 ET | 600 | 19.67 |
| 02:58 ET | 200 | 19.63 |
| 03:00 ET | 100 | 19.66 |
| 03:02 ET | 533 | 19.705 |
| 03:03 ET | 100 | 19.71 |
| 03:05 ET | 200 | 19.69 |
Apr 9, 2024
NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease, from 8:00AM ET on Tuesday Apr 09, 2024 by Dow Jones
8:00AM ET on Tuesday Apr 09, 2024 by Dow Jones
Apr 1, 2024
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer, from 8:00AM ET on Monday Apr 01, 2024 by Dow Jones
8:00AM ET on Monday Apr 01, 2024 by Dow JonesPress Release: NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer, from 8:00AM ET on Monday Apr 01, 2024 by Dow Jones
8:00AM ET on Monday Apr 01, 2024 by Dow Jones
Mar 25, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
NewAmsterdam Pharma Company NV | 1.8B | -7.3x | --- |
Kymera Therapeutics Inc | 2.1B | -14.0x | --- |
Ardelyx Inc | 1.5B | -21.2x | --- |
Recursion Pharmaceuticals Inc | 1.8B | -4.7x | --- |
Arvinas Inc | 2.3B | -5.2x | --- |
Intellia Therapeutics Inc | 2.1B | -3.9x | --- |
Company Information
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.
Contact Information
- Headquarters
- Gooimeer 2-35NAARDEN, Netherlands 1411 DC
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- William Lewis
- Chief Executive Officer, Executive Director
- Michael Davidson
- Interim Chief Financial Officer
- Louise Kooij
- Chief Operating Officer
- Douglas Kling
- Chief Scientific Officer, Non-Executive Director
- John Kastelein
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.8B |
|---|---|
Revenue (TTM) | $14.5M |
Shares Outstanding | 89.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.71 |
Book Value | $6.32 |
P/E Ratio | -7.3x |
Price/Sales (TTM) | 123.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,461.62% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
